Previous 10 | Next 10 |
AVITA Medical, Inc. (RCEL) Q4 2022 Earnings Conference Call February 23, 2023 04:30 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Jim Corbett - Chief Executive Officer Sean Ekins - Acting Chief Financial Officer Conference Cal...
AVITA Medical press release ( NASDAQ: RCEL ): Q4 GAAP EPS of -$0.21 beats by $0.07 . Revenue of $9.46M (+36.3% Y/Y) beats by $0.63M . Our commercial revenue, which excludes BARDA revenue, increased by 37% to $9.4 million in the three months ended December 31, 2022, com...
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “ Company ”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies ...
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced toda...
Summary Shares have fallen by 83% over the past 3 years and are down 13% over the past year. Q3 "beat and raise" along with appointment of a highly experienced CEO could turn sentiment around here. Soft tissue repair launch in 2H 23 addresses an opportunity 3 to 4x the size of burns...
AVITA Medical ( NASDAQ: RCEL ) on Thursday announced some management changes, including the departure of its chief operating officer and CFO. RCEL CFO Michael Holder will step down while senior VP of finance, Sean Ekins, will serve as interim CFO, the company said in a statemen...
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical” or the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and aut...
AVITA Medical ( NASDAQ: RCEL ) on Monday said it had submitted a premarket approval application to the U.S. FDA seeking an expansion of the indication of its RECELL system to treat vitiligo. Vitiligo is a skin disease that causes discoloration and loss of skin color in patches. Th...
VALENCIA, Calif., and MELBOURNE, Australia, Dec. 19, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced tod...
VALENCIA, Calif. and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, toda...
News, Short Squeeze, Breakout and More Instantly...
VALENCIA, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its second quarter 2024 financia...
VALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the Joseph M. Still Burn Center at Doctors Hosp...
2024-06-02 14:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...